Compare Novo Nordisk A/S (NVO) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Novo Nordisk A/S trades at $45.08 (market cap $198.57B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.79. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| NVO | XLY | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | — |
52-Week High | $63.98 | $124.52 |
52-Week Low | $35.29 | $105.64 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
XLY trades at $113.99, down 0.8% today amid bearish technical signals with 18 sell indicators versus 3 buy signals. The ETF maintains 100% analyst buy consensus despite missing key valuation metrics. Recent news highlights consumer discretionary sector opportunities, with XLY positioned as a potential sleeper ETF for Q3 2026 given resilient consumer spending trends and economic conditions.
The outlook remains cautiously optimistic with strong analyst support, though technical weakness and sector concentration risks warrant monitoring. Upside potential exists from consumer spending resilience and economic broadening, while downside risks include market volatility and inflationary pressures affecting discretionary purchases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
